Skip to main content

Table 3 Patients and tumor characteristics of the selected studies

From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Authors
(year of publication) [reference]
Number of patients underwent SBRTType of StudyPrimary Tumor siteNumber of metastases underwent to SBRT (upper limit)Type of oligometastases and organ involved (liver, lung, bone, nodes, brain…)Metastases size
(cm)
SBRT
(median total dose/fraction)
Biologically equivalent dose (Median value)Systemic Therapy
Weickhardt et al. (2012) [29]25RetrospectiveNSCLC<=4Oligoprogressive (Brain,Lung)N.S.15–54Gy, median 40GyN.S.Crizotinib, Erlotinib
Iyengar et al. (2014) [23]24 (52 lesions)Phase IINSCLC<=3Oligorecurrent (Lung; Liver;
Kidney; Bone;
Adrenal;
Mediastinum)
N.S.19–40/1–555.1–72Erlotinib
Borghetti et al. (2019) [25]49RetrospectiveNSCLC<=4Oligoprogressive (Brain, Lung, Bone)N.S.mean 80 Gy, range 60–178 Gy> 60N.S.
Qiu et al. (2017) [24]46RetrospectiveNSCLC< 5OligoprogressiveN.S.N.S.N.S.N.S.
Rossi et al. (2019) [26]30RetrospectiveNSCLCN.S.OligoprogressiveN.S.N.S.N.S.Afatinib, Gefitinib
Weiss et al. (2019) [30]25RetrospectiveNSCLCN.S.OligoprogressiveN.S.N.S.N.S.Erlotinib
Chan OSH et al. (2018) [31]18Phase IINSCLC34OligoprogressiveN.S.N.S.N.S.TKI therapy
Xu et al. (2018) [27]51RetrospectiveNSCLCN.S.OligoprogressiveN.S.27–21–33-37.5/1–1–3-565.8Gefitinib, Erlotinib, Icotinib